Table 3 Identified patient access schemes in the Asian-Pacific region (excluding Australian examples)
From: Patient access schemes in Asia-pacific markets: current experience and future potential
Country | Drug | Indication | Company | Payer | Type | Details | Source |
|---|---|---|---|---|---|---|---|
South Korea | Migraine medications | Migraine headaches | Not specified | National health insurance | Financially-based | Pharmaceutical companies maintained their PLS status via voluntary price cuts | Lee et al. 2012 [22] |
Hypertension medications | Hypertension | Not specified | National health insurance | Financially-based | 285 of the 1226 hypertension drugs instituted price reductions following reassessment of clinical usefulness & price. Drugs were delisted if they failed to show a level of clinical usefulness or if their prices were higher than 80 percentile of the highest price among drugs containing the same ingredients. If the company accepted price cuts, the price was to be lowered to the level of the 80 percentile within 3Â years | Lee et al. 2012 [22] | |
Hyperlipidemia medications - therapeutic class | Hyperlipidemia | Not specified | National health insurance | Financially-based | Pharmaceutical companies maintained their PLS status via voluntary price cuts | Lee et al. 2012 [22] | |
New Zealand | Beta-interferon products, glatiramer acetate | Multiple sclerosis | Bayer | PHARMAC | Financially-based | Extended coverage for a specified number of patients | Raftery 2008 [23] |
Trastuzumab | Breast cancer | Roche | PHARMAC | Financially-based | Established separate hospital program to fund distribution of cancer drugs | Raftery 2008 [23] | |
Imatinib | Chronic myeloid leukemia | Novartis | PHARMAC | Financially-based | Offered overall price reduction | Raftery 2008 [23] | |
Atorvastatin | Hypertension | Pfizer | PHARMAC | Financially-based | Price volume agreements; manufacturer committed to pay for the drug if the sales exceed a fixed threshold | Antonanzas et al. 2011 [24] | |
| Â | Adalimumab | Arthritis | Abbott Laboratories NZ Ltd | PHARMAC | Financially-based | Adalimumab spending is probably overstated due to a risk sharing agreement between the sponsor and PHARMAC, which involves rebates paid by the sponsor once Government spending reaches a certain level | Access Economics report for Arthritis New Zealand 2010 [25] |